Supplemental Table S2. Results of Sensitivity Analysis according to Probability

Sensitivity analysis[a]	Strategy	Cost, USD	Incremental cost, USD	Effectiveness, QALYs	Incremental effectiveness, QALYs	ICER, $/QALY	NMB, USD
Probability of lobectomy with ES							
0.1735	ES	9,590	797	23.23	0.11	7,299	454,964
	SD	8,793		23.12			453,577
0.3470	ES	9,208	415	23.26	0.15	2,852	456,072
	SD	8,793		23.12			453,577
0.5205	ES	8,826	33	23.30	0.18	182	457,180
	SD	8,793		23.12			453,577
Probability of lobectomy with SD							
0.1543	ES	9,208	23	23.26	0.12	187	456,072
	SD	9,186		23.14			453,674
0.3086	ES	9,208	219	23.26	0.15	2,852	456,072
	SD	8,989		23.12			453,577
0.4628	ES	9,208	807	23.26	0.17	4,750	456,072
	SD	8,401		23.09			453,481

USD, US dollar; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; ES, early screening; SD, symptomatic detection.
[a]For each probability value, 75% to 125% of the base case value was used.

Copyright © 2024 Korean Endocrine Society